<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02046655</url>
  </required_header>
  <id_info>
    <org_study_id>UHR-11</org_study_id>
    <nct_id>NCT02046655</nct_id>
  </id_info>
  <brief_title>Corifollitropin Alfa Compared to Daily rFSH in Poor Responders Undergoing ICSI</brief_title>
  <official_title>Corifollitropin Alfa Compared to Daily Rec FSH in Poor Responders Undergoing ICSI Using a GnRH Antagonist Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <brief_summary>
    <textblock>
      Corifollitropin alfa has been shown to result in significantly more oocytes compared to daily
      recombinant follicle stimulating hormone (recFSH) (Devroey et al., 2009), probably due to the
      higher circulating FSH activity during the first days of stimulation. For this reason, the
      use of corifollitropin alfa might be beneficial in poor responders in whom the number of
      oocytes retrieved is crucial for success.

      The purpose of this study is to evaluate the effectiveness of corifollitropin alfa treatment
      compared to daily recFSH in terms of the number of oocytes retrieved in a defined population
      of poor responder patients undergoing intracytoplasmic sperm injection (ICSI) using
      gonadotrophin releasing hormone (GnRH) antagonists.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of retrieved oocytes</measure>
    <time_frame>36 h after human chorionic gonadotrophin (hCG) administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate (evidence of intrauterine sac with fetal heart activity at 6-8 weeks of gestation)</measure>
    <time_frame>At 6-8 weeks of gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of embryos transferred</measure>
    <time_frame>2 days following oocyte retrieval</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Subfertility</condition>
  <arm_group>
    <arm_group_label>Corifollitropin alfa group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On day 2 of the cycle, a single subcutaneous (SC) dose of 150 μg Corifollitropin alfa (Elonva) will be administered.
GnRH antagonist (Orgalutran) 0.25 mg/day flexible initiation by a follicle of 14mm.
A daily dose of recFSH (450 IU/day) will be used from day 8 of stimulation until the day of hCG, if necessary.
Triggering of final oocyte maturation will be performed using 250 μg of rechCG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rec FSH group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>On day 2 of the cycle, daily SC dose of min 450 IU recFSH (Puregon) will be administered.
GnRH antagonist (Orgalutran) 0.25 mg/day , flexible initiation by a follicle of 14mm.
Triggering of final oocyte maturation will be performed using 250 μg of rechCG.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corifollitropin alfa</intervention_name>
    <arm_group_label>Corifollitropin alfa group</arm_group_label>
    <other_name>Elonva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rFSH</intervention_name>
    <arm_group_label>rec FSH group</arm_group_label>
    <other_name>Puregon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Proven poor responders of couples with an indication for COS

          2. ≥ 18 and &lt; 45 years of age

          3. BMI ≥ 18 and ≤ 32 kg/m2

          4. Regular spontaneous menstrual cycle (24-35 days)

          5. Availability of ejaculatory sperm (use of donated and/or cryo-preserved sperm is
             allowed)

        Exclusion Criteria:

          1. PGD or PGS

          2. TESE
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Efstratios M Kolibianakis, MD, MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unit for Human Reproduction, 1st Dept. of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unit for Human Reproduction, 1st Dept of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2013</study_first_submitted>
  <study_first_submitted_qc>January 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <last_update_submitted>May 13, 2014</last_update_submitted>
  <last_update_submitted_qc>May 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>E.M. Kolibianakis</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

